IN-VIVO AND IN-VITRO ANTI-INFLAMMATORY AND ANTI-ARTHRITIC ACTIVITY OF SYNTHETIC CIS-9 AND CIS-10 CETYL MYRISTOLEATE (CMO) ISOMERS IN MICE

Nutraceuticals comprising cis-9-cetylmyristoleate (CMO) was reported to block inflammation and prevent adjuvant-induced arthritis in rats. Latter it was also used to reduce knee pain in patients suffering with osteoarthritis. In our earlier study, we have reported the synthesis of pure cis-9 and cis-10 CMO isomers form oleic acid and undecenoic acid by chemo-enzymatic transformations and their anti-arthritic effect in-vivo using Freunds complete adjuvant (FCA chronic) and carrageen induced paw edema (acute) in male Wistar rats. In this context, we tested the effects of these synthetic cis-9 and cis-10 CMO isomers for in-vitro anti-inflammatory activity using stimulated RAW264.7 mouse macrophage cell line, and destabilization of medial meniscus (DMM) surgery-induced osteoarthritis in C57WT mice. Further, we have treated mouse macrophage cells with CMO isomers to investigate the expression profile of secreted inflammatory cytokines. Both CMOs exhibited dose-dependent reduction of secretion of TNFα, IL-6, nitric oxide, prostaglandin E₂ and leukotriene B_4, in response to lipopolysaccharide (LPS) in mouse macrophage cells. These vegetable oil origin synthetic cis-9 and cis-10 CMO isomers can be potential sustainable non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of osteoarthritis and inflammatory diseases.